ICON与Anthropic达成多年合作，将Claude接入临床试验流程

Oil extends slide as U.S.-Iran talks raise hopes of lasting de-escalation
DUBLIN - ICON plc (NASDAQ:ICLR) announced today a multi-year collaboration with Anthropic to integrate Claude AI capabilities throughout the clinical trial process, according to a press release statement.
The partnership will focus on developing four production capabilities within ICON’s Orbis AI platform. These include site intelligence and study planning tools for site selection and study feasibility, predictive intelligence for real-time detection of enrollment risks and operational signals, protocol optimization to reduce amendments and accelerate study startup, and ecosystem integration allowing clients to access ICON’s insights within Claude.
ICON will deploy Claude across its organization through a role-based rollout, with Claude Code for developers, Claude for knowledge teams, and Claude Science for scientific and clinical teams.
Barry Balfe, Chief Executive Officer of ICON plc, stated: "We are determined to lead AI acceleration of clinical trials. Working with Anthropic gives us direct access to frontier AI capability and the people who build it."
Pip White, Head of Ireland, UK and Northern Europe at Anthropic, noted that study enrollment causes delays in up to 80% of trials and represents a significant operational bottleneck in clinical development.
ICON is a clinical research organization headquartered in Dublin, Ireland. The company employed approximately 40,200 employees in 99 locations across 55 countries as of June 30, 2026.
The collaboration will support ICON’s AI strategy by strengthening the intelligence layer that powers Orbis, driving productivity through automation of high-volume activities, and developing domain-specific agents for clinical development workflows.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.